Current Status of Off-label Use of Denosumab in Bone Tumor and Bone Diseases / 肿瘤防治研究
Cancer Research on Prevention and Treatment
;
(12): 316-320, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-986720
ABSTRACT
Denosumab is a monoclonal antibody against the receptor activator of nuclear factor-κB (RANK) ligand (RANKL) that significantly inhibits osteoclast activity and has been approved to treat osteoporosis, giant cell tumor of bone, and prophylactic as well as therapeutic entities for bone metastasis. However, the imbalance of RANKL/RANK/OPG has also been implicated in the pathogenesis of several other rare bone diseases and tumor-like disorders, including aneurysmal bone cyst, fibrous dysplasia of bone, and Langerhans cell histiocytosis. Nevertheless, there have been various clinical reports although these diseases have not been approved for indications. The review aims to summarize the available evidence for the off-label use of denosumab in metabolic bone diseases and tumor-like disorders and provide a reference for clinical diagnosis and treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Cancer Research on Prevention and Treatment
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS